Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616122 · ClinicalTrials.gov registry record · Phase 1
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00616122 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 32 participants.
The verdict
NCT00616122, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib when given together with cyclophosphamide and methotrexate to see how well they work in treating patients with metastatic breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cyclophosphamide
- DRUG methotrexate
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-03-01 |
| Est. Completion | 2012-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616122
The ClinicalTrials.gov registry entry for NCT00616122 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00616122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616122 about?
NCT00616122 is a clinical study titled "Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer". RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividi...
What is the current status of trial NCT00616122?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-03-01. Estimated completion is 2012-12-01.
What interventions are being tested in trial NCT00616122?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cyclophosphamide (DRUG), methotrexate (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00616122?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.